The table below shows the Low Price Pharma Stocks List – Pharma Penny Stocks India based on the Highest Market Capitalization.
| Stock Name | Market Cap (₹ Cr) | Close Price (₹) |
| Piramal Pharma Ltd | 27,018.46 | 197.62 |
| Marksans Pharma Ltd | 9,600.73 | 198.79 |
| Sun Pharma Advanced Research Co Ltd | 3,951.37 | 124.6 |
| SeQuent Scientific Ltd | 3,776.33 | 152.05 |
| Gujarat Themis Biosyn Ltd | 2,663.11 | 272.63 |
| Morepen Laboratories Ltd | 2,633.47 | 48.36 |
| Alembic Ltd | 2,445.59 | 94.24 |
| Suven Life Sciences Ltd | 2,371.55 | 119.46 |
| Indoco Remedies Ltd | 1,844.78 | 224.34 |
| SMS Pharmaceuticals Ltd | 1,678.06 | 191.84 |
Table of Contents
Best Low Price Pharma Stocks
The table below shows the Best Low Price Pharma Stocks based on 1 Year Return.
| Stock Name | Close Price (₹) | 1-Year Return (%) |
| Desh Rakshak Aushdhalaya Ltd | 31.99 | 360.29 |
| Bacil Pharma Ltd | 38.12 | 249.08 |
| Venmax Drugs and Pharmaceuticals Ltd | 20.31 | 208.66 |
| Shukra Pharmaceuticals Ltd | 246.1 | 179.53 |
| Astal Laboratories Ltd | 82 | 110.58 |
| Tiaan Consumer Ltd | 6.3 | 110 |
| Oxygenta Pharmaceutical Ltd | 73.4 | 102.54 |
| Gujarat Terce Laboratories Ltd | 70.85 | 97.79 |
| Jagsonpal Pharmaceuticals Ltd | 215.47 | 76.41 |
| Welcure Drugs and Pharmaceuticals Ltd | 7.89 | 75.33 |
Low Price Pharma Stocks Nse
The table below shows Low Price Pharma Stocks Nse based on 1 Month Return.
| Stock Name | Close Price (₹) | 1-Month Return (%) |
| Desh Rakshak Aushdhalaya Ltd | 31.99 | 44.36 |
| Chemo Pharma Laboratories Ltd | 91.31 | 17.33 |
| Cian Healthcare Ltd | 3.86 | 16.51 |
| Brawn Biotech Ltd | 19.4 | 14.67 |
| Shukra Pharmaceuticals Ltd | 246.1 | 13.3 |
| JFL Life Sciences Ltd | 19.85 | 8 |
| Tiaan Consumer Ltd | 6.3 | 7.01 |
| Trident Lifeline Ltd | 268.15 | 4 |
| Fabino Enterprises Ltd | 28.95 | 3.21 |
| Vista Pharmaceuticals Ltd | 10.08 | -0.76 |
Low Price Pharma Stocks
The table below shows Pharma Penny Stocks based on the Highest Daily Volume.
| Stock Name | Close Price (₹) | Daily Volume (Shares) |
| Piramal Pharma Ltd | 197.62 | 7,097,184 |
| Morepen Laboratories Ltd | 48.36 | 3,585,598 |
| Medico Remedies Ltd | 56 | 2,423,001 |
| Syncom Formulations (India) Ltd | 15.73 | 2,419,388 |
| Marksans Pharma Ltd | 198.79 | 1,817,619 |
| Sun Pharma Advanced Research Co Ltd | 124.6 | 1,738,926 |
| Nectar Lifesciences Ltd | 27.23 | 1,547,653 |
| Johnson Pharmacare Ltd | 0.97 | 1,346,986 |
| Gennex Laboratories Ltd | 12.97 | 1,183,242 |
| Remedium Lifecare Ltd | 2.29 | 1,116,513 |
Low Price Pharma Stocks India
The table below shows Pharma Penny Stocks India based on the PE Ratio.
| Stock | Close Price (₹) | PE Ratio |
| Ind Swift Ltd | 14.2 | 1.19 |
| IND Swift Laboratories Ltd | 97.75 | 2.4 |
| Par Drugs and Chemicals Ltd | 95.64 | 7.63 |
| Transchem Ltd | 41.52 | 8.59 |
| Alpa Laboratories Ltd | 106.79 | 9.08 |
| Tyche Industries Ltd | 138.85 | 11.09 |
| Godavari Drugs Ltd | 83.51 | 12.03 |
| Vasundhara Rasayans Ltd | 237.1 | 12.9 |
| Wanbury Ltd | 188.29 | 14.05 |
| Medico Intercontinental Ltd | 41.44 | 16.51 |
Low Price Pharma Stocks Under 10 Rs
The table below shows Pharma Penny Stocks Under 10 Rs.
| Stock Name | Close Price (₹) | 1Y Return (%) |
| Hemo Organic Ltd | 9 | -0.44 |
| Welcure Drugs and Pharmaceuticals Ltd | 7.89 | 75.33 |
| Ajooni Biotech Ltd | 7.14 | 33.96 |
| Tiaan Consumer Ltd | 6.3 | 110 |
| Patron Exim Ltd | 5.86 | -34.82 |
| Zenith Healthcare Ltd | 4.93 | 1.65 |
| Cian Healthcare Ltd | 3.86 | -83.21 |
| Achyut Healthcare Ltd | 2.96 | -27.43 |
| Vivanta Industries Ltd | 2.95 | -29.43 |
| EVOQ Remedies Ltd | 2.94 | -75.4 |
Low Price Pharma Stocks List – FAQs
1. Which are the Best Pharma Stocks?
- Best Pharma Stocks #1: Piramal Pharma Ltd
- Best Pharma Stocks #2: Marksans Pharma Ltd
- Best Pharma Stocks #3: Sun Pharma Advanced Research Co Ltd
- Best Pharma Stocks #4: SeQuent Scientific Ltd
- Best Pharma Stocks #5: Gujarat Themis Biosyn Ltd
The stocks mentioned are ranked according to their one-year performance.
2. Is it good to invest in Pharma Penny Stocks?
Investing in pharmaceutical penny stocks carries a high risk due to volatility, limited liquidity, and uncertainty. It’s crucial to research thoroughly, consider your risk tolerance, and diversify your portfolio wisely.
3. What are the Low Price NSE Pharma Stocks?
Pharmaceutical stocks encompass companies researching, developing, manufacturing, and distributing drugs and healthcare products. A stock price below 50 Rs may be considered “low-priced” in this sector, but it’s essential to evaluate such stocks based on various factors before investing.
4. What is the future of Pharma Penny Stocks?
The future of Pharma Penny Stocks is uncertain and highly speculative, influenced by regulatory changes, drug developments, and market sentiment. Potential investors should exercise caution and conduct thorough research before investing.
Introduction to Low Price Pharma Stocks List
Low Price Pharma Stocks List – Highest Market Capitalization
Piramal Pharma Ltd
The Market Cap of Piramal Pharma Ltd is ₹27,018.46 crore. The stock’s 1-month return is -15.12%, while its 1-year return is 54.45%. It is currently 72.82% away from its 52-week high.
Piramal Pharma Ltd is a leading pharmaceutical company engaged in contract development and manufacturing, complex generics, and consumer healthcare. The company has a strong global presence and provides high-quality pharmaceutical products and services. With a focus on innovation and R&D, Piramal Pharma continues to expand its offerings in specialty pharmaceuticals and healthcare solutions.
The company’s diverse portfolio includes APIs, drug formulations, and consumer healthcare products. With an emphasis on sustainable growth and strategic acquisitions, Piramal Pharma is continuously strengthening its market position. The company’s commitment to quality and regulatory compliance makes it a trusted partner in the global pharmaceutical industry.
Marksans Pharma Ltd
The Market Cap of Marksans Pharma Ltd is ₹9,600.73 crore. The stock’s 1-month return is -20.32%, while its 1-year return is 30.01%. It is currently 52.92% away from its 52-week high.
Marksans Pharma Ltd is a globally recognized pharmaceutical company specializing in the development, manufacturing, and marketing of generic pharmaceutical formulations. The company operates across multiple international markets, with a strong presence in regulated markets such as the US, UK, and Australia. Its product portfolio spans multiple therapeutic segments, including pain management, cardiovascular health, and gastrointestinal treatments.
Marksans Pharma focuses on innovation and strategic expansion to maintain its competitive edge. By leveraging advanced manufacturing capabilities and robust R&D investments, the company continues to develop cost-effective and high-quality pharmaceutical products. It aims to strengthen its position in the global pharmaceutical market through continued product launches and geographical expansion.
Sun Pharma Advanced Research Co Ltd
The Market Cap of Sun Pharma Advanced Research Co Ltd is ₹3,951.37 crore. The stock’s 1-month return is -20.32%, while its 1-year return is -68.20%. It is currently 14.00% away from its 52-week high.
Sun Pharma Advanced Research Company (SPARC) is a research-driven pharmaceutical entity focused on novel drug discovery and development. As an innovation arm of Sun Pharmaceutical Industries, SPARC is dedicated to developing cutting-edge pharmaceutical solutions, including new chemical entities (NCEs) and novel drug delivery systems (NDDS). The company’s R&D efforts primarily target oncology, neurology, ophthalmology, and dermatology.
Despite facing challenges in recent financial performance, SPARC continues to invest heavily in drug development and strategic partnerships. The company aims to deliver breakthrough therapies that address unmet medical needs and improve patient outcomes. With an emphasis on regulatory approvals and clinical advancements, SPARC remains committed to innovation in the global pharmaceutical industry.
Best Low Price Pharma Stocks – 1 Year Return
Desh Rakshak Aushdhalaya Ltd
The Market Cap of Desh Rakshak Aushdhalaya Ltd is ₹14.64 crore. The stock’s 1-month return is 44.36%, while its 1-year return is 360.29%. It is currently 360.29% away from its 52-week high.
Desh Rakshak Aushdhalaya Ltd is a pharmaceutical company engaged in the manufacturing and distribution of Ayurvedic and herbal medicines. The company focuses on providing natural healthcare solutions based on traditional Indian medicine. Its product portfolio includes various herbal remedies, tonics, and wellness supplements, catering to a growing market of consumers seeking alternative medicine.
The company has experienced significant stock performance growth over the past year, driven by increased interest in Ayurvedic and herbal healthcare solutions. With a commitment to research and innovation, Desh Rakshak Aushdhalaya Ltd aims to expand its market presence and product offerings. The company is leveraging the rising consumer preference for natural and herbal treatments to enhance its growth prospects.
Bacil Pharma Ltd
The Market Cap of Bacil Pharma Ltd is ₹24.33 crore. The stock’s 1-month return is -10.60%, while its 1-year return is 249.08%. It is currently 249.08% away from its 52-week high.
Bacil Pharma Ltd is a pharmaceutical company engaged in the production and distribution of a range of pharmaceutical formulations. The company focuses on supplying high-quality medicines, catering to both domestic and international markets. Its portfolio includes tablets, capsules, and liquid formulations used in various therapeutic segments.
Despite facing a decline in monthly performance, Bacil Pharma has witnessed significant one-year growth, indicating strong market confidence in its potential. The company continues to explore new opportunities for expansion, particularly in emerging markets. With a focus on research-driven innovation, Bacil Pharma aims to establish itself as a key player in the pharmaceutical sector.
Venmax Drugs and Pharmaceuticals Ltd
The Market Cap of Venmax Drugs and Pharmaceuticals Ltd is ₹10.70 crore. The stock’s 1-month return is -36.08%, while its 1-year return is 208.66%. It is currently 223.92% away from its 52-week high.
Venmax Drugs and Pharmaceuticals Ltd is a growing pharmaceutical company specializing in the manufacturing and distribution of pharmaceutical formulations. The company serves both domestic and international markets, offering a diverse range of generic and branded medications. Its focus areas include antibiotics, analgesics, and nutritional supplements.
Despite recent declines in its monthly stock performance, Venmax Drugs and Pharmaceuticals Ltd has shown strong long-term growth. The company is working to expand its production capabilities and strengthen its presence in global markets. With an emphasis on quality assurance and regulatory compliance, Venmax Drugs aims to enhance its reputation and market share in the pharmaceutical industry.
Low Price Pharma Stocks Nse – 1 Month Return
Chemo Pharma Laboratories Ltd
The Market Cap of Chemo Pharma Laboratories Ltd is ₹12.66 crore. The stock’s 1-month return is 17.33%, while its 1-year return is 29.90%. It is currently 74.76% away from its 52-week high.
Chemo Pharma Laboratories Ltd is a pharmaceutical company engaged in manufacturing and distributing a wide range of pharmaceutical formulations. The company specializes in producing high-quality generic medicines for various therapeutic segments, including antibiotics, anti-inflammatory drugs, and pain management solutions. It has built a strong reputation for compliance with regulatory standards and ensuring the efficacy of its products.
Despite experiencing a positive one-month return, the stock remains significantly below its 52-week high, reflecting volatility in market trends. The company is actively expanding its product portfolio and market reach, leveraging its expertise in pharmaceutical formulations. With an increasing demand for affordable and effective medicines, Chemo Pharma Laboratories Ltd aims to enhance its market presence and drive sustainable growth.
Cian Healthcare Ltd
The Market Cap of Cian Healthcare Ltd is ₹10.02 crore. The stock’s 1-month return is 16.51%, while its 1-year return is -83.21%. It is currently 29.97% away from its 52-week high.
Cian Healthcare Ltd is a pharmaceutical company specializing in manufacturing and marketing a wide range of healthcare products. The company’s portfolio includes prescription drugs, over-the-counter (OTC) medicines, nutraceuticals, and personal care products. It has a strong presence in both domestic and international markets, catering to various therapeutic needs.
While the company has shown positive returns in the past month, its one-year performance has been significantly negative. This decline indicates challenges in market stability and competition. Despite this, Cian Healthcare Ltd continues to focus on product innovation and market expansion strategies. The company aims to improve its financial performance by enhancing operational efficiencies and exploring new business opportunities.
Brawn Biotech Ltd
The Market Cap of Brawn Biotech Ltd is ₹6.14 crore. The stock’s 1-month return is 14.67%, while its 1-year return is -17.52%. It is currently 25.16% away from its 52-week high.
Brawn Biotech Ltd is a pharmaceutical company engaged in manufacturing and exporting a diverse range of pharmaceutical formulations. The company provides affordable medicines across multiple therapeutic categories, including cardiology, neurology, and dermatology. With a commitment to quality and innovation, Brawn Biotech aims to strengthen its foothold in the healthcare industry.
Although the stock has seen a positive monthly return, its one-year performance has been in decline. This suggests a period of instability and market fluctuations. However, the company remains focused on growth and expansion, particularly in international markets. By leveraging research and development, Brawn Biotech Ltd is striving to create a strong pipeline of new products to meet evolving market demands.
Pharma Penny Stocks – Highest Day Volume
Morepen Laboratories Ltd
The Market Cap of Morepen Laboratories Ltd is ₹2,633.47 crore. The stock’s 1-month return is -28.49%, while its 1-year return is -0.29%. It is currently 25.45% away from its 52-week high.
Morepen Laboratories Ltd is a well-established pharmaceutical company involved in the research, development, and manufacturing of pharmaceutical formulations, active pharmaceutical ingredients (APIs), and diagnostic devices. The company has a strong presence in both domestic and international markets, catering to various segments, including over-the-counter (OTC) drugs and branded generics.
Despite a decline in its one-month return, the company’s stock has maintained relative stability over the past year. Morepen Laboratories Ltd continues to invest in research and development, with a focus on innovation and expansion. The company is also strengthening its diagnostic business and increasing its API production capabilities to sustain long-term growth.
Medico Remedies Ltd
The Market Cap of Medico Remedies Ltd is ₹419.40 crore. The stock’s 1-month return is -28.54%, while its 1-year return is -34.39%. It is currently 60.92% away from its 52-week high.
Medico Remedies Ltd is a pharmaceutical company engaged in the manufacturing and marketing of a wide range of formulations, including tablets, capsules, syrups, and injectables. The company supplies its products to both domestic and international markets, serving various therapeutic segments such as cardiology, gastroenterology, and dermatology.
The stock has experienced a significant decline in both its monthly and annual performance, reflecting market challenges. However, Medico Remedies Ltd continues to focus on expanding its product line and entering new markets. With a commitment to quality and compliance, the company aims to strengthen its position in the pharmaceutical industry and improve its financial performance over time.
Syncom Formulations (India) Ltd
The Market Cap of Syncom Formulations (India) Ltd is ₹1,506.82 crore. The stock’s 1-month return is -16.67%, while its 1-year return is 16.95%. It is currently 43.65% away from its 52-week high.
Syncom Formulations (India) Ltd is a well-established pharmaceutical company in India, engaged in manufacturing and marketing a diverse range of medicines. With over 200 formulations across various therapeutic categories, the company has gained a strong presence in both domestic and international markets. Its product portfolio includes tablets, capsules, syrups, ointments, injections, and effervescent tablets, catering to multiple healthcare needs. The company’s state-of-the-art manufacturing unit in Pithampur, Madhya Pradesh, is WHO-GMP certified, ensuring compliance with global quality standards.
The company’s focus on quality, affordability, and innovation has contributed to its growth over the years. Syncom exports its products to several countries, further expanding its footprint beyond India. With an emphasis on research and development, it continues to introduce new and effective pharmaceutical solutions. By maintaining high standards in manufacturing and distribution, the company has positioned itself as a reliable name in the Indian pharmaceutical industry.
Pharma Penny Stocks India – PE Ratio
Ind-Swift Ltd
The Market Cap of Ind-Swift Ltd is ₹79.57 crore. The stock’s 1-month return is -21.64%, while its 1-year return is -18.62%. It is currently 8.98% away from its 52-week high.
Ind-Swift Ltd, founded in 1986, is a pharmaceutical company known for its expertise in developing, manufacturing, and marketing a wide range of medicines. The company operates in multiple therapeutic segments, including cardiology, neurology, anti-infectives, anti-diabetics, and nutraceuticals. Ind-Swift’s commitment to innovation and quality has helped it maintain a strong reputation in the industry. The company has obtained ISO 9001-2008 and WHO-GMP certifications, reinforcing its focus on quality standards.
Apart from its presence in the Indian market, Ind-Swift has expanded globally, exporting its pharmaceutical products to Europe, Canada, Australia, South Africa, and Russia. The company has a well-established institutional division that supplies medicines to government hospitals and defense establishments. This widespread reach allows Ind-Swift to serve various healthcare needs across different sectors. Despite challenges in the stock market, the company continues to focus on growth through product development, regulatory compliance, and strategic expansions.
Ind-Swift Laboratories Ltd
The Market Cap of Ind-Swift Laboratories Ltd is ₹515.53 crore. The stock’s 1-month return is -17.18%, while its 1-year return is -10.44%. It is currently 19.98% away from its 52-week high.
Ind-Swift Laboratories Ltd specializes in the production of Active Pharmaceutical Ingredients (APIs) and is known for its high-quality manufacturing processes. With a focus on research-driven solutions, the company supplies APIs to leading pharmaceutical firms in India and international markets. Ind-Swift Laboratories has built a strong reputation by complying with stringent global quality regulations such as USFDA, WHO-GMP, and European standards.
The company’s portfolio includes a range of products used in cardiovascular, anti-inflammatory, and central nervous system treatments. Through strategic partnerships and exports, Ind-Swift Laboratories has established a significant presence in key global markets. It continues to expand its research capabilities to develop new molecules and formulations. By investing in cutting-edge technology and maintaining high production standards, the company aims to strengthen its position in the pharmaceutical sector while ensuring sustainable growth.
Par Drugs and Chemicals Ltd
The Market Cap of Par Drugs and Chemicals Ltd is ₹135.54 crore. The stock’s 1-month return is -52.50%, while its 1-year return is -53.75%. It is currently 6.62% away from its 52-week high.
Par Drugs and Chemicals Ltd is a pharmaceutical company engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs) and bulk drugs. With a focus on high-quality production and innovation, the company caters to both domestic and international markets. Its product portfolio includes a variety of APIs used in analgesics, antipyretics, and anti-inflammatory medications. The company follows stringent quality control measures to ensure the safety and efficacy of its products.
Par Drugs and Chemicals has expanded its reach by exporting pharmaceutical ingredients to multiple countries. The company’s research and development initiatives focus on improving production efficiency and developing new formulations. Despite recent challenges in stock performance, Par Drugs and Chemicals continues to maintain its commitment to quality and innovation. By leveraging its expertise in bulk drug manufacturing, the company aims to strengthen its position in the pharmaceutical sector and capitalize on growth opportunities.
Low Price Pharma Stocks Under 10 Rs
Hemo Organic Ltd
The Market Cap of Hemo Organic Ltd is ₹3.47 crore. The stock’s 1-month return is -9.49%, while its 1-year return is -0.44%. It is currently 11.80% away from its 52-week high.
Hemo Organic Ltd is a pharmaceutical company involved in the production and distribution of herbal and organic healthcare products. The company focuses on developing natural and herbal formulations to cater to the growing demand for alternative medicine. With an emphasis on quality and sustainability, Hemo Organic Ltd has positioned itself as a trusted provider of herbal remedies and wellness products.
The company’s product line includes herbal supplements, Ayurvedic formulations, and organic medicines, catering to both domestic and international markets. Hemo Organic Ltd invests in research and development to enhance its product offerings and improve production efficiency. Despite being a small-cap stock, the company continues to explore new opportunities for growth. As consumer interest in herbal and organic healthcare products increases, Hemo Organic Ltd aims to capitalize on this trend by expanding its market reach and strengthening its brand presence.
Welcure Drugs and Pharmaceuticals Ltd
The Market Cap of Welcure Drugs and Pharmaceuticals Ltd is ₹74.82 crore. The stock’s 1-month return is -25.54%, while its 1-year return is 75.33%. It is currently 109.84% away from its 52-week high.
Welcure Drugs and Pharmaceuticals Ltd is an Indian pharmaceutical company engaged in the research, development, and manufacturing of a wide range of medicines. The company focuses on producing high-quality pharmaceutical products that cater to multiple therapeutic segments, including anti-infectives, pain management, and dermatology. With a commitment to affordability and accessibility, Welcure Drugs aims to serve a broad customer base.
The company has made significant strides in expanding its operations by leveraging modern manufacturing techniques and strict quality control measures. With a growing presence in both domestic and international markets, Welcure Drugs continues to invest in research and innovation to develop new formulations. The company’s impressive stock performance over the past year reflects investor confidence in its long-term growth potential. By maintaining a strong focus on quality and customer satisfaction, Welcure Drugs and Pharmaceuticals Ltd is well-positioned for further expansion.
Ajooni Biotech Ltd
The Market Cap of Ajooni Biotech Ltd is ₹129.01 crore. The stock’s 1-month return is -3.11%, while its 1-year return is 33.96%. It is currently 65.28% away from its 52-week high.
Ajooni Biotech Ltd is a company engaged in the production of animal nutrition and healthcare products. It specializes in manufacturing cattle feed, poultry feed, and related nutritional supplements. The company’s focus on research and development has allowed it to create high-quality, science-backed formulations that improve livestock health and productivity.
By leveraging modern manufacturing facilities and stringent quality control standards, Ajooni Biotech has built a strong reputation in the animal healthcare industry. Its products are widely used in the dairy and poultry sectors, contributing to improved livestock growth and milk production. With a growing demand for quality animal nutrition, the company continues to expand its product line and explore new market opportunities. Ajooni Biotech’s strong financial performance and commitment to innovation position it well for future growth in the agribusiness and animal healthcare sectors.
We hope you’re clear on the topic, but there’s more to explore in stocks, commodities, mutual funds, and related areas. Here are important topics to learn about.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.
